KR101594979B1 - Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. - Google Patents
Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. Download PDFInfo
- Publication number
- KR101594979B1 KR101594979B1 KR1020150116742A KR20150116742A KR101594979B1 KR 101594979 B1 KR101594979 B1 KR 101594979B1 KR 1020150116742 A KR1020150116742 A KR 1020150116742A KR 20150116742 A KR20150116742 A KR 20150116742A KR 101594979 B1 KR101594979 B1 KR 101594979B1
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- obesity
- extract
- group
- food
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 235000020824 obesity Nutrition 0.000 title claims abstract description 50
- 241001082360 Euphorbia supina Species 0.000 title claims abstract description 8
- 239000000284 extract Substances 0.000 title abstract description 79
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 230000003579 anti-obesity Effects 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 230000004069 differentiation Effects 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 210000001789 adipocyte Anatomy 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 238000009825 accumulation Methods 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 230000004580 weight loss Effects 0.000 claims description 13
- 102000016267 Leptin Human genes 0.000 claims description 10
- 108010092277 Leptin Proteins 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 229940039781 leptin Drugs 0.000 claims description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 10
- 102000011690 Adiponectin Human genes 0.000 claims description 9
- 108010076365 Adiponectin Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 102000000536 PPAR gamma Human genes 0.000 claims description 6
- 108010016731 PPAR gamma Proteins 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 235000008452 baby food Nutrition 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 2
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims description 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 230000006303 immediate early viral mRNA transcription Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims 8
- 239000002031 ethanolic fraction Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 24
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 abstract description 15
- 229960002722 terbinafine Drugs 0.000 abstract description 15
- 210000000577 adipose tissue Anatomy 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000005194 fractionation Methods 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 239000013585 weight reducing agent Substances 0.000 abstract description 6
- 230000006372 lipid accumulation Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 16
- 206010004194 Bed bug infestation Diseases 0.000 description 14
- 241001327638 Cimex lectularius Species 0.000 description 12
- 230000035508 accumulation Effects 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 7
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 7
- 229940030275 epigallocatechin gallate Drugs 0.000 description 7
- 239000002038 ethyl acetate fraction Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002037 dichloromethane fraction Substances 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- -1 xylitone Chemical compound 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 241001414835 Cimicidae Species 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 239000012223 aqueous fraction Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000193388 Bacillus thuringiensis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000221017 Euphorbiaceae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000593508 Garcinia Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229940109529 pomegranate extract Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000233622 Phytophthora infestans Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
The present invention relates to an anti-obesity food composition and a composition for weight reduction comprising an extract or fraction of Euphorbia supina Raf. As an active ingredient, an anti-obesity pharmaceutical composition, . In addition to inhibiting the differentiation and lipid accumulation of adipose tissue and the fractionation of the terbinafine according to the present invention, the obesity-suppressing effect such as weight and fat tissue weight reduction in the obesity-induced group is excellent, Can be usefully used to prevent, ameliorate or treat various obesity-related diseases.
Description
The present invention relates to an anti-obesity food composition and a composition for weight reduction comprising an extract or fraction of Euphorbia supina Raf. As an active ingredient, an anti-obesity pharmaceutical composition, .
Obesity is a state of excess body fat, refers to the state of body fat is 25% (male), 30% (female) or more. In modern society, the eating habits have been improved and the nutritional intake through the food has been improved. As a result, life expectancy and quality of life have been improved. However, over consumption of food, decrease in physical exercise due to changes in means of transportation and westernization of eating habits Obesity patients are increasing rapidly every year. The World Health Organization (WHO) explains that worldwide obesity is caused by a decrease in body movements due to an increase in the frequency of intake of foods with low nutrient content, high calorie content, and changes in means of transport and lifestyle. That is, the fundamental cause of obesity is the energy imbalance in which energy accumulation occurs because the calories consumed are larger than the calories consumed. Obesity is also seen as a risk factor for adult diseases and is involved in diseases such as diabetes, arteriosclerosis, hypertension, stroke, heart failure, and various inflammatory tumors. Obesity is accompanied by a serious weight gain, which can also affect joints and bones due to excessive weight gain, leading to skeletal abnormalities. For this reason, obesity is not only an external problem, but also a serious health problem.
Prevention of obesity should be controlled through balanced diet and regular eating habits, and physical exercise should be increased to increase basal metabolic rate to ensure normal metabolism. As obesity becomes known as a problem in modern society, the word diet is attracting much attention. There are many ways to lose weight by taking advantage of the fact that people who are obese are interested in weight loss. Typical examples are fasting and fasting, enzymes, liposuction, laxatives, diuretics, and treatments. These methods provide easy and comfortable weight loss to modern people, but it is common for side effects to occur. In general, modern people are interested only in quick and easy diet, but they are not interested in fundamental therapy. Therefore, they overlook clear and scientific reasoning and the mechanism of metabolism and nutritional physiological approach with fundamental therapeutic purpose If you only focus on weight loss, you will have another problem and a yo-yo phenomenon of weight. As such, obesity can be regarded as an independent disease, but as it causes other diseases, it is becoming more popular, easy to use, easy to lose weight, less side effects such as yo-yo phenomena It is time to develop a therapeutic agent.
To date, obesity treatments for weight loss are classified as appetite suppressants, fat absorption inhibitors, and energy consumption stimulants. Among them, pharmacotherapy using an appetite suppressant such as amphetamine inducing agent is a temporary problem in which the ability to inhibit appetite is not sustained, and problems such as headache, insomnia, hypertension, tension, anxiety, hallucination symptoms, dizziness, ≪ / RTI > A representative drug is sibutramine. It acts on the hypothalamus of the brain and is known to cause an appetite suppressing effect. Serotonin and norepinephrine (Norepinephrine) inhibit the reuptake of the nervous hormones that regulate the appetite, thereby reducing appetite, preventing overeating, and inhibiting high energy intake to reduce body weight. Most of these appetite suppressants prohibit the use of these drugs in cardiovascular patients because of the adverse effects of elevated blood pressure, which can put a strain on the heart. Also, the fat absorption inhibitor is Orlistat. Orlistat is a lipase inhibitor secreted by the pancreas and digestive system. It inhibits the lipase secreted from the pancreas and digestive system, inhibiting the absorption of fat and inhibiting the accumulation of fat in the body. However, orlistat may inhibit the absorption of fat-soluble vitamins, which can lead to vitamin imbalance, gastric intussusception, gas-induced gastric bloating, and oil-bladder stools, thereby causing inconvenience to the digestive system.
Therefore, in recent years, there has been a need to develop a composition which enables not only a therapeutic agent used in an artificial method, but also a herb medicine derived from a natural product to be ingested in the form of a universal food. Particularly attention is focused on the treatment of obesity derived from natural products without side effects.
On the other hand, Euphorbia supina Raf. Is an annual herbaceous plant belonging to the Euphorbiaceae. Its main stem extends along the ground and is 10 ~ 25cm long. There are some hairs with leaves and reddish brown spots at the center. It contains white fluid. Leaves are long oval with length of 5 ~ 10mm and width of 4 ~ 6mm, with sawtooth on the edge, spread horizontally and arranged in two lines. The upper surface of the leaf is dark green, the back is rusty white, and the petiole is very short. The bedbugs are widely distributed in temperate and tropical regions of Korea, China, Japan, Southeast Asia, and North and South America. It has excellent antioxidant, antitumor, and sedative effects and is widely used for various kinds of cancer, asthma, diabetes, heart disease, kidney disease, malignant headache and mental anxiety. It has excellent hemostatic effect, It is known to be effective in treating blood and hematuria. As mentioned above, various pharmacological effects of aphids are known, but it has not yet been elucidated whether the extracts and fractions of the phytophthora infestans have anti-obesity activity.
Accordingly, the inventors of the present invention have conducted studies on extracts and fractions of the genus Bacillus thuringiensis in order to develop a new drug. As a result, the present inventors have completed the present invention by confirming that the extract or fraction of the genus Bacillus thuringiensis has an excellent anti-obesity effect.
It is an object of the present invention to provide a pharmaceutical composition for anti-obesity which comprises as an active ingredient an extract of Curcuma longa thunbergii or a fraction thereof.
Another object of the present invention is to provide an anti-obesity food composition comprising an extract of Ajiji tsukuni or a fraction thereof as an active ingredient, and a composition for weight loss comprising the extract or fraction as an active ingredient.
In order to accomplish the above object, the present invention provides a pharmaceutical composition for anti-obesity comprising an extract of Curcuma longa thunbergii or a fraction thereof as an active ingredient.
In addition, the present invention provides an anti-obesity food composition comprising as an active ingredient an extract of Ajiwa tsubaki or a fraction thereof.
In addition, the present invention provides a composition for weight loss comprising an extract of Curcuma longa larvae or a fraction thereof as an active ingredient.
In addition to inhibiting the differentiation and lipid accumulation of adipose tissue and the fractionation of the terbinafine according to the present invention, the obesity-suppressing effect such as weight and fat tissue weight reduction in the obesity-induced group is excellent, Can be usefully used to prevent, ameliorate or treat various obesity-related diseases.
BRIEF DESCRIPTION OF THE DRAWINGS FIG.
FIG. 2 is a graph showing the cell survival rate of adipocytes in the treatment of a terbinafine extract (Vehicle: normal control, EtOH: rice terbinafine extract treatment group, EGCG: positive control group).
FIG. 3 is a graph showing the cell survival rate of adipocytes in the treatment of the terrestrial broad-leaved fraction (Vehicle: normal control group, CH 2 Cl 2 : treatment group of dichloromethane fraction of baby root, EtOAc: 2 O: cleavage site water bed fraction treatment group, EGCG: positive control group).
FIG. 4 is a graph showing fat accumulation rate in adipocytes in the treatment of aripipterous moth larvae extract (Vehicle: normal control, MDI: negative control, EtOH: EGCG: positive control).
FIG. 5 is a graph showing fat accumulation rate in adipocytes during the treatment of the petioles of the landing zone (Vehicle: Normal control, MDI: Negative control, CH 2 Cl 2 : Dipeptidyl dichloromethane fraction treatment group, EtOAc: Ethyl acetate fraction treated group, H 2 O: teratomas water fraction treated group, EGCG: positive control group).
FIG. 6 is a graph showing the results of ELISA assay of mouse blood leptin levels in the treatment of the terrestrial broad-leaved birds (Normal: normal control, HFD: obese-induced group, EtOH: Ethyl acetate fraction treated group, H 2 O: disrupted ground water bed fraction treatment group, GC: positive control group).
FIG. 7 is a graph showing the results of measurement of the level of adiponectin in mouse blood by ELISA in the treatment of the infected ground wing fraction.
FIG. 8 is a graph showing the results of real-time PCR measurement of PPAR-γ levels in mouse liver tissues during the treatment with the extracts or fractions of A.beta.
FIG. 9 is a graph showing the results of real-time PCR measurement of C / EBP alpha levels in mouse liver tissues in the treatment of the terbinafine extract or fraction.
FIG. 10 is a graph showing the results of real-time PCR measurement of PPAR-γ levels in mouse adipose tissues in the treatment of the terbinafine extract or fraction.
11 is a graph showing the results of real-time PCR measurement of C / EBP alpha levels in mouse adipose tissues in the treatment of the terbinafine extract or fraction.
Hereinafter, the present invention will be described in detail.
The present invention relates to the use of Euphorbia supina Shelf . ) Extract or fraction thereof as an active ingredient.
The Euphorbia of the present invention supina Shelf . ) Is a perennial herb that belongs to the Euphorbiaceae and is widely distributed in temperate and tropical regions such as Korea, China, Japan, Southeast Asia, and North and South America. It is known that the bedbugs of the baby are excellent in antioxidant, anticancer, detoxifying, soothing, and hemostatic functions.
The term "extract " in the present invention means a preparation obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating by evaporating the leaching solution. The extract is obtained by extracting the diluted solution or concentrate of the extract, the dried product obtained by drying the extract, Or purified water.
The above-mentioned baby bedbug can be used without limitation such as cultivated or marketed, and can be used as it is or can be used by drying. As the drying method, it is possible to use both blanket, shade, hot air drying and natural drying.
The above-mentioned baby bird bed bug extract or fraction can be extracted or fractionated from various parts of the baby bed bed, and is preferably extracted or fractionated from flowers, leaves, stems, roots or outposts of baby bed bugs, It is extracted or fractionated from leaves, stems or outposts of the ground worms, and most preferably extracted or fractionated from the outposts of the worm worms.
The baby cotyledon extracts or fractions can be obtained from nature using methods of extraction, separation and fractionation known in the art. The baby cotyledon extract or fraction may be obtained according to various extraction solvents and extraction methods. As an appropriate solvent for obtaining the extract or fraction from the infant bed cavity, water or an organic solvent may be used, and any pharmaceutically acceptable organic solvent may be used. Examples of the solvent include water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, etc. These solvents may be used alone or as a mixture of two or more thereof . Preferably, methanol or ethanol (alcohol) can be used, and more preferably, ethanol can be used.
Preferably, the extraction temperature for obtaining the above-mentioned terbinafine extract is 50 to 100 < 0 > C. In one embodiment of the present invention, the extract of A. terbinafine was obtained at a temperature of 70 DEG C, but is not limited thereto. The extraction method may include various methods such as a hot water extraction method, a cold extraction method, a reflux cooling extraction method, a solvent extraction method, a steam distillation method, an ultrasonic extraction method, a leaching method and a pressing method, but is not limited thereto, Extraction method.
The above-mentioned pit stopper fractions can be obtained as individual solvent fractions through a process of separating an organic solvent from a non-polar to polar fraction. Suitable solvents for the fractionation of the soil bedbug fractions may be water, ethanol, methanol, hexane, chloroform, dichloromethane, ethyl acetate, butanol or mixtures thereof, preferably water, dichloromethane, ethyl acetate Most preferably water, ethyl acetate or a mixture thereof.
The baby cotyledon extracts or fractions can be obtained by freezing, heating and filtering at room temperature by conventional methods known in the art, or the solvent may be further evaporated, spray dried or lyophilized. In addition, the infant extract or fraction may be produced in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying. The extract or fraction may be further purified by further chromatography using various chromatographies such as silica gel column chromatography, thin layer chromatography, high preformance liquid chromatography and the like Can be obtained.
Therefore, the term "birdwatching" or "fragrance" used in the present invention includes all the extracts, fractions and purified products obtained in each step of extraction, fractionation or purification, their diluted solutions, concentrates or dried products.
In the present invention, the term "obesity " refers to a state having excess body fat, which means that the body fat is 25% (male) or 30% (female) or more of body weight.
The term "anti-obesity" in the present invention means treating, preventing or ameliorating an obese condition.
According to one embodiment of the present invention, the Ajiwi groundbreaking extract or fraction inhibits the differentiation of adipose precursor cells into adipocytes, reduces the amount of leptin expression in the blood, and increases the expression level of adiponectin. In addition, the expression level of PPAR-γ protein, C / EBP α protein, C / EBP β protein and C / EBP δ protein, which are transcription factors involved in adipocyte differentiation, . Therefore, the extracts or fractions of the infant of the present invention may be useful as medicines and food compositions for preventing or treating obesity-related diseases or complications due to obesity.
The inventive terbinafine extract or fractions include, but are not limited to, metabolic syndrome, hypertriglyceridemia, hyperlipidemia, hypolipidemia, angina pectoris, myocardial infarction, sexual dysfunction, sleep apnea syndrome, premenstrual syndrome, Hyperlipidemia, diabetes mellitus, hypertension, impaired glucose tolerance, coronary artery thrombosis, diaphoresis, depression, anxiety, hyperlipidemia, hypertension, diabetes mellitus, , Anorexia nervosa, polycystic ovarian disease, atherosclerosis, atherosclerosis, atherosclerosis, gallbladder disease such as atherosclerosis, gallstone disease, anorexia nervosa, anorexia nervosa, Dermatological conditions such as reproductive disorders, infections, varicose veins, epidermal hyperplasia and eczema, insulin resistance, chronic arteriolar obstruction, orthopedic surgery May be used to prevent or treat injury, thromboembolic events, cardiovascular disease, urinary disorders, lipid syndromes, hyperglycemia, and stress at least one obesity-related disorder selected from the group consisting of.
The present invention also provides a method for preventing, ameliorating or treating obesity, abdominal obesity or visceral fat accumulation in each part of the body, and preferably for preventing, improving or treating visceral fat accumulation Can be used. The abdominal obesity or visceral fat accumulation includes, but is not limited to, living in a chair for a long time, or caused by lack of exercise, alcohol consumption, stress or the like.
Preferably, the pomegranate extract or fraction is contained in an amount of 0.01 to 95% by weight, more preferably 1 to 80% by weight, based on the total weight of the pharmaceutical composition of the present invention.
The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the art. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably, but not limited to, those disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA). Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitone, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When the pharmaceutical composition is formulated or formulated, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. The components may be added to the active ingredient, i. E., The pomegranate extract or fraction, either independently or in combination.
The term "administering" as used herein means providing a pharmaceutical composition of the present invention to a subject in any suitable manner.
The present invention also provides pharmaceutical compositions comprising an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, physician or other clinician, Or a therapeutically effective amount which is sufficient to induce relief. It will be apparent to those skilled in the art that the therapeutically effective dose and the frequency of administration for the pharmaceutical compositions of the present invention will vary with the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. The pharmaceutical composition of the present invention may be administered to the individual by various routes. But are not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, oral, intracardiac, intramedullary, intradermal, transdermal, intestinal, subcutaneous, sublingual or topical administration.
The pharmaceutical composition of the present invention may be administered at a dose of 1 to 10,000 mg / kg / day, preferably 1 to 2000 mg / kg / day, and may be administered once a day or divided into several doses.
The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, oral, rectal or intravenous, intramuscular, subcutaneous.
In addition, the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers for the prevention or treatment of obesity, obesity-related diseases or complications .
In addition, the present invention provides an anti-obesity food composition comprising as an active ingredient an extract of Ajiwa tsubaki or a fraction thereof.
The inventive terbinafine extract or fraction can be used as a health functional food, a food additive or a dietary supplement.
In the case of using the baby food extract or fraction of the present invention as a food additive, it may be suitably used according to a conventional method such as adding the baby food extract or fraction as it is, or mixing it with other food or food ingredients .
In addition, the amount of mixture of the above-mentioned active ingredients, the soil bed bug extract or the fractions, may be suitably changed according to the purpose of use (prevention, health or therapeutic treatment), and the above- By weight, preferably 0.01 to 95% by weight, more preferably 1 to 80% by weight. As a specific example, in the production of a food or beverage, the rice terra cotta extract or fraction of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less based on the raw material.
There is no particular limitation on the type of the food, but examples of the food to which the present invention is added include a meat, a sausage, a bread, a chocolate, a candy, a snack, a confectionery, a pizza, a ramen, Dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, and the like.
When the food composition of the present invention is prepared as a beverage, it may contain additional ingredients such as various flavors or natural carbohydrates such as ordinary beverages. Examples of the natural by-products include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame, and the like. The natural carbohydrate is contained in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
The food composition of the present invention can be used for various foods, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusters, stabilizers, preservatives, glycerin, Carbonation agents used in beverages, etc., and may include, but is not limited to, natural fruit juices, fruit juice beverages, and flesh for the manufacture of vegetable beverages. These components may be used independently or in combination. The proportion of the above additives is not particularly limited, but is preferably within the range of 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
For long-term consumption intended for health and hygiene purposes or health control purposes, the food composition of the present invention has no problem in terms of safety and can be taken for a long period of time.
In addition, the present invention provides a composition for weight loss comprising an extract of Curcuma longa larvae or a fraction thereof as an active ingredient.
The composition for weight reduction according to the present invention may be a pharmaceutical composition or a food composition. When formulated into a pharmaceutical composition, various auxiliaries used in medicine such as carriers and other additives such as stabilizers, emollients, emulsifiers and the like may be added as needed unless adversely affecting the active ingredient. The formulations may be any formulations suitable for pharmaceutical preparations of herbal medicine, including tablets, pills, capsules, granules, powders, excipients, precursors, infiltrates and the like.
As used herein, the term "prophylactic " means any act that inhibits obesity or delays progression by administration of the composition of the present invention.
As used herein, the term "treatment" refers to any action in which the administration of the composition of the present invention improves or alleviates obesity.
Terms not otherwise defined herein have meanings as commonly used in the art to which the present invention belongs.
Hereinafter, the present invention will be described in detail with reference to Examples and Preparation Examples. However, the following examples and preparative examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and preparative examples.
Example One. Baby bedbug ( Euphorbia supina Shelf .) Preparation of extract
2.5 kg of Euphorbia supina Raf. Plant which was dried in the air was repeatedly extracted with 70% ethanol at 70 ° C three times using a reflux extracting apparatus to obtain 250 g (yield: 10.06%) of a baby grasshopper extract. For example.
Example 2. Baby bedbug Fraction Produce
The procedure of suspending 250 g of the A. niger extract obtained in Example 1 in distilled water and separating the dichloromethane (CH 2 Cl 2 ) layer was repeated three times. The dichloromethane layer thus obtained was combined and concentrated under reduced pressure to obtain 128 g (yield: 51.2%) of a dichloromethane fraction in the form of a flower bed. Ethyl acetate (CH 3 COOC 2 H 5 ) was added to the remaining water layer and fractionation was carried out in the same manner as above. The filtrate was concentrated under reduced pressure and lyophilized to obtain 48 g (yield: 19.2%) of the ethyl acetate fraction 74 g (yield: 29.6%) of the fractions were obtained and used in the following examples.
The production process of the baby cotto leaves extract and fractions is briefly shown in Fig.
Example 3. Cytotoxicity and viability analysis
3-1. Lipo-precursor cells (3 T3 - L1 ) And preparation
3T3-L1 cells are lipogenic precursor cells widely used to study the metabolism of adipocytes. As 3T3-L1 cells are actively differentiated, fat accumulation in adipocytes is also actively induced. 3T3-L1 cells were purchased from ATCC (American Type Culture Collection, USA). Cell lines obtained from ATCC were cultured in DMEM medium containing 10% bovine calf serum (BCS) and 1% penicillin in an incubator maintained at 37 ° C with 5% CO 2 . When the cells were stabilized through two or more subcultures, they were used for the experiment.
3-2. Cytotoxicity and viability analysis
(MTT (3- (4,5-dimethylthiazol-2-yl) -1,2,3,4-tetrahydronaphthalene-2-yl) -benzonitrile was used in order to determine the cytotoxicity, -2,5-diphenyl tetrazolium bromide) analysis was performed. 3T3-L1 cells were inoculated into a 48-well plate at a concentration of 2 × 10 5 cells / well, and the culture medium was changed once every two days and cultured to 100% confluent. The cultured cells were treated with 4, 20, and 100 μg / ml of each of the pituitary extracts, respectively. The dichloromethane fraction, the ethyl acetate fraction, and the pituitary extract fraction were 0.8, 4, 20 ㎍ / ㎖, and cultured at 37 ° C and 5% CO 2 for 8 days. After incubation, absorbance was measured using MTT buffer. (EGCG) treated with Epigallocatechin gallate (EGCG) was used as a positive control group, and the above procedure was repeated three times as a normal control group Lt; / RTI > Cell viability was calculated by the following formula 1, and the results are shown in FIG. 2 and FIG.
[ Equation One]
Cell viability (%) = (absorbance of sample-treated group / absorbance of control group) x 100
As shown in FIG. 2 and FIG. 3, it was confirmed that the active ingredient of the present invention was not toxic at high concentration.
Example 4. Baby bedbug Extract or Fraction Identification of inhibitory effect on adipocyte differentiation
The fat accumulation rate was checked to determine if the extracts or fractions of the terrestrial bandlets inhibit the differentiation of 3T3-L1 cells into adipocytes. To confirm this, stabilized 3T3-L1 cells were plated in a 48-well plate at a density of 2 × 10 5 cells / well and cultured. The cells were maintained for 2 days at 100% confluent time. 3T3-L1 cells were treated with 10% Fetal Bovine Serum (FBS) containing 1% MDI (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 μM dexamethasone, Penicillin-containing DMEM medium for induction of differentiation into adipocytes for 2 days. After 48 hours of culture, the cells were cultured in DMEM medium containing 10% FBS and 1% penicillin containing 1 μg / mL of insulin for 2 days. During the adipocyte differentiation process, the extracts of the rice seedlings and the leaves of the rice seedlings were treated at the concentrations of 4, 20 and 100 μg / mL, and the dichloromethane fraction, the ethyl acetate fraction, Water fractions were treated at 0.8, 4, and 20 μg / mL in culture. Then, the degree of adipocyte differentiation was observed on the 8th day when the differentiation was completed. As a normal control group, vehicle treated group (Vehicle) was used. Negative control group was treated with IBMX, Insulin, Dexamethasone to induce lipid accumulation (MDI).
In order to observe the degree of differentiation of adipocytes, Oil Red O staining, which is specific to lipid droplet, was performed. Specifically, the medium was removed from adipocyte differentiation-induced cells and fixed with 10% formalin for 1 hour at room temperature. Then washed with 60% isopropanol and each well was thoroughly dried. Oil Red O dye (60% Oil Red O stock, 40% sterilized distilled water) was treated for 1 hour and washed twice with 60% isopropanol and once with sterile distilled water. For the elution of the combined Oil Red O, it was treated with 100% isopropanol for 10 minutes, and the absorbance of the eluate was measured at 520 nm.
Fat accumulation rate in adipocyte was calculated by the following
[ Equation 2]
Fat accumulation rate (%) = (absorbance of sample-treated group / absorbance of control group) x 100
As shown in FIG. 4 and FIG. 5, it was confirmed that fat accumulation in adipocytes was inhibited in a concentration-dependent manner by the treatment with the active ingredient of the present invention, the soil bed band extract, the ethyl acetate fraction, the dichloromethane fraction and the water fraction. Therefore, it can be seen that the pituitary gland extract or the pit bark of the present invention inhibits the differentiation of adipose precursor cells into adipocytes, and thus the prevention or treatment effect of obesity is excellent.
Example 5. Baby bedbug Extract or Fraction Check your weight loss effect
5-1. Construction of Obesity-Induced Mouse Model
5 weeks old C57BL / 6J male mice (20 ~ 25g) were purchased from Samtako (Osan, Korea) and were allowed to freely eat solid feed and water for 1 week. ± 10%), constant temperature (22 ± 2 ℃), and 12-hour cycle. After the adaptation period for one week, the animals were divided into 12 groups. The normal control group (normal), obesity induction group treated with 45% high fat diet (HFD) (0.8, 4, 20 mg / kg, ESEA + HFD) and the control group (0.8, 4, 20 mg / kg, ESEE + HFD) prepared in Example 2, 4, 20 mg / kg, ESH 2 O + HFD) and the positive control group, Garminia cambogia extract treatment (200 mg / kg, GC + HFD).
Obesity group, obesity group, obesity group, obesity group, obesity group, obesity group, obesity group, obesity group, obesity group, After dissolving in cellulose (sterilized distilled water + carboxymethylcellulose), 45% high fat diet was freely taken and oral administration of extract or fraction was performed once a day for 6 weeks. Normal control diet was given freely, and 0.9% of saline was orally administered to the obese group. A mouse model was constructed as described above and used in the following examples.
5-2. Check your weight change
In order to confirm the anti-obesity effect of the extracts or fractions of the birds, the body weight was measured at intervals of one week after the start of the experiment and the start of the experiment in the mouse experimental group constructed by the method of Example 5-1, Table 3 shows the results.
As shown in Tables 1 to 3, it was confirmed that the body weight of the obese-induced group was significantly increased compared with the normal control group. In contrast, the weight gain of the group treated with Garcinia cambogia was 34.13% lower than that of the obese group.
Specifically, as shown in Table 1, the body weight gain was decreased by 13.52% and 34.54%, respectively, compared with the obesity-induced group, and as shown in Table 2, the ethyl acetate fraction fraction Were decreased by 23.02% and 52.27%, respectively, in comparison with the obese group. In addition, as shown in Table 3, it was confirmed that the body weight gain was reduced by 20.21% and 52.28% in the group treated with the parasitic infestation water, compared with the obesity-induced group.
Therefore, the extract of the present invention, which is the active ingredient of the present invention, decreased the body weight to a significant level, and the weight loss was significantly larger in the 20 mg / kg-treated group than the control group . In addition, 20mg / kg - treated group showed higher weight loss than the positive control group. From these results, it was confirmed that the extracts or fractions of the present invention were excellent in anti-obesity effect by inducing weight loss.
Example 6 - Baby bedbug Extract or Fraction Long-term weight and fat tissue weight reduction effects
In order to confirm the anti-obesity effect of the A. niger extract or fraction of the present invention, the weight of liver tissue, kidney tissue, white epididymal fat tissue and spleen tissue of the experimental group constructed in 5-1 above was measured. Specifically, after the experiment period of 5-1, the mouse model was sacrificed by ether anesthesia, the abdomen was excised, each tissue was extracted, and blood and foreign substances were removed using physiological saline and the weight was measured. Are shown in Tables 4 to 6 below.
As shown in Tables 4 to 6, the weight of white epididymal adipose tissue was significantly increased in the obese-induced group compared to the normal control group, but the weight of the treated group was significantly decreased in the group treated with Garcinia cambogia . In addition, it was confirmed that the weight of white epididymal adipose tissue was significantly decreased in the concentration -
Accordingly, the present invention relates to a method for producing an anti-obesity food composition, an anti-obesity food composition, or a composition for weight loss, which is effective for decreasing the weight of adipose tissue.
Example 7 - Measurement of triglyceride concentration in serum
In order to confirm the anti-obesity effect of the inventive terbinafine extract, the concentration of triglyceride in the blood of the mouse model was measured after completion of the experiment of the above example.
Blood was collected after the experiment was terminated and cardiac blood was drawn after anesthesia. The collected blood was allowed to stand at room temperature for 30 minutes and then centrifuged at 4 ° C for 3 minutes at 3000 rpm for 10 minutes to obtain serum (triglyceride ), Total cholesterol, high density lipoprotein-cholesterol and low density lipoprotein-cholesterol concentrations were measured using Asanpharm (Korea) kit, Table 9 shows the results.
As shown in Tables 7 to 9, the concentration of triglyceride, total cholesterol, and LDL-cholesterol in the serum of the obese-induced group was higher than that of the normal control group, and the concentration of HDL-cholesterol was found to be low. On the other hand, the concentration of triglyceride, total cholesterol and LDL-cholesterol in serum was lower and the concentration of HDL-cholesterol was higher in obesity-induced group than that in obesity-induced group Respectively.
Therefore, the inventive terbinafine extract or fraction thereof significantly reduces the concentration of triglyceride, total cholesterol and LDL-cholesterol in the test animal in a concentration-dependent manner and significantly increases the concentration of HDL-cholesterol in a concentration-dependent manner, And the obesity effect is excellent.
Example 8 - Baby bedbug Extract or Fraction Serum Leptin And Depotectin Check the effect on concentration
The leptin and adiponectin concentrations in the blood of animal models were measured after completion of the experiment of the above example in order to confirm the anti-obesity effect of the infant extracts or fractions. Leptin and adiponectin are both secreted proteins in adipocytes.
As in Example 7, blood collected from a mouse was centrifuged to obtain serum, and concentrations of leptin and adiponectin were measured using an ELISA kit. The results are shown in FIGS. 6 and 7.
As shown in FIG. 6, serum leptin levels were significantly increased in the obese-induced group compared to the normal control group, and the positive control group was significantly decreased as compared with the obese-induced group. In addition, it was confirmed that the concentration of leptin in the serum was decreased in a concentration-dependent manner in the group of administration of the active ingredient of the present invention, that is, the terbinafine extract or fraction, in comparison with the obese-induced group.
As shown in FIG. 7, serum concentrations of adiponectin were significantly lower in the obese-induced group than in the normal control group, and the group treated with Garcinia cambogia extract, which was a positive control, was significantly increased as compared with the obese-induced group. In addition, it was confirmed that the concentration of adiponectin in the serum was significantly increased in the group of administration of the active ingredient of the present invention as a control group, or in the fraction-administered group, as compared with the obesity-induced group.
Thus, the baby bedbug extract or fraction may have an anti-obesity effect due to the effect of decreasing the leptin level of blood and the effect of increasing the level of adiponectin.
Example 9 - Baby bedbug Extract or Fraction Confirming the inhibitory effect of obesity gene expression
In order to confirm whether or not the extract of the present invention is inhibiting obesity-associated genes, RNA was extracted from liver tissue and white epididymal adipose tissue, and expression of PPAR-γ, C / EBP α gene was analyzed by Real-time PCR Respectively.
Specifically, first, a lysis buffer was added to the liver tissue and white epididymal adipose tissue of the mice to homogenize them, and then a supernatant was obtained using a centrifuge. In the supernatant CHCl 3 After adding the solution, the supernatant was obtained again by using a centrifuge. Isopropanol was added to the supernatant thus obtained, and the supernatant was removed using a centrifugal separator. After washing with 75% ethanol, a precipitate RNA was obtained. This precipitate was dissolved in water without Rnase and used. RNA was synthesized by cDNA synthesis kit and real-time PCR was performed.
Real-time PCR was performed using the StepOnePlus TM Instrument was used. First, add 10 μl of SYBR® Green Reagents, 0.4 μl of forward primer (10 pmol / l), 0.4 μl of reverse primer (10 pmol / μl), 7.2 μl of water without Rnase and 2 μl of template (30 ng / μl) -time PCR was performed on a plate and then proceeded using a StepOne Softewear 2.3v. The PCR conditions were 95 cycles of 10 minutes, 95 cycles of 10 seconds, and 60 cycles of 1 minute at 40 cycles. The results are shown in FIGS.
As shown in FIG. 8 to FIG. 11, it was confirmed that the extracts or fractions of A. terbinafine according to the present invention inhibited the expression of PPAR-γ and C / EBP α in liver and white epididymal adipose tissue in a concentration-dependent manner.
Therefore, it can be seen that the extract of Ajiwa tendonhopper of the present invention inhibits the expression of obesity factors, and thus the effect of preventing or treating obesity, obesity-related diseases or complications will be excellent.
Formulation example 1 - Manufacture of pharmaceutical preparations
Acid production
A mixture of 20 mg of the infant groundbug extract or fraction, 100 mg of lactose, and 10 mg of talt was mixed and filled into airtight bags to prepare powders.
Tablet manufacture
The tablets were prepared by mixing 10 mg of cotyledonberry extract or fraction, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate and then tableting according to a conventional preparation method.
Capsule preparation
According to a conventional capsule preparation method, 10 mg of the extract or fraction of Aji, 9 mg of crystalline cellulose, 14.8 mg of lactose and 0.2 mg of magnesium stearate were mixed and filled in gelatin capsules to prepare capsules.
Injection manufacturing
1 ampoule per (2mL) according to the conventional method for preparing injections were prepared in a baby bed bugs land extract or fraction 10mg, mannitol 180mg, injectable sterile distilled water 2,974mg and Na 2 HPO 4 · 2H 2 O 26mg.
Liquid preparation
In accordance with the usual preparation method of the liquid preparation, 20 mg of the extracts or fractions of Piggerychus, 10 g of isomerized sugar and 5 g of mannitol were dissolved in purified water, and the lemon flavor was added in an appropriate amount. Then, purified water was further added thereto, adjusted to a total volume of 100 mL, filled in a brown bottle, and sterilized to prepare a liquid preparation.
Formulation example 2 - Manufacture of food preparation
Health food manufacturing
100 mg of vitamin A mixture, vitamin A acetate 70 g, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 g,
Health drink manufacturing
100 g of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, 0.2 g of vitamin B1 0.25 g, 0.3 g of vitamin B2 and a predetermined amount of water were mixed and heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2L container, sealed sterilized, and refrigerated to prepare a health drink . At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, the mixture ratio may be arbitrarily varied according to the demand, the demanded country, the intended use, and the regional or national preference.
Although the present invention has been described in terms of the preferred embodiments mentioned above, it is possible to make various modifications and variations without departing from the spirit and scope of the invention. It is also to be understood that the appended claims are intended to cover such modifications and changes as fall within the scope of the invention.
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150116742A KR101594979B1 (en) | 2015-08-19 | 2015-08-19 | Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. |
PCT/KR2016/009193 WO2017030419A1 (en) | 2015-08-19 | 2016-08-19 | Composition including euphorbia supina raf. extract or fraction as active ingredient for preventing or treating obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150116742A KR101594979B1 (en) | 2015-08-19 | 2015-08-19 | Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101594979B1 true KR101594979B1 (en) | 2016-02-17 |
Family
ID=55457806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150116742A KR101594979B1 (en) | 2015-08-19 | 2015-08-19 | Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101594979B1 (en) |
WO (1) | WO2017030419A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180106023A (en) | 2017-03-17 | 2018-10-01 | 한남대학교 산학협력단 | A pharmaceutical composition for preventing or treating obesity comprising seaweed extract and rosemary extract as an active ingredient |
KR102197241B1 (en) * | 2019-09-20 | 2020-12-31 | (주)엘파운더 | Composition for antioxidant and lipid differentiation inhibitory activity by ampk phosphorylation from fraction of ceramium kondoi |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110120813A (en) * | 2010-04-29 | 2011-11-04 | 주식회사 코스메카코리아 | Cosmetic composition comprising euphorbia supina for improving skin wrinkle |
KR101269590B1 (en) * | 2010-12-31 | 2013-06-05 | 한국생명공학연구원 | Composition comprising Euphorbia supina extract for preventing and treating inflammentary or allergic disease |
KR101359728B1 (en) * | 2013-03-25 | 2014-02-24 | 원광대학교산학협력단 | Composition containing fraction of euphorbia humifusa willd or euphorbia supina rafin for treating or preventing inflammatory disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100974584B1 (en) * | 2010-05-03 | 2010-08-09 | 조남철 | Health assistance food included the euphorbia humifusa wild and the manufacturing method therof |
-
2015
- 2015-08-19 KR KR1020150116742A patent/KR101594979B1/en active IP Right Grant
-
2016
- 2016-08-19 WO PCT/KR2016/009193 patent/WO2017030419A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110120813A (en) * | 2010-04-29 | 2011-11-04 | 주식회사 코스메카코리아 | Cosmetic composition comprising euphorbia supina for improving skin wrinkle |
KR101269590B1 (en) * | 2010-12-31 | 2013-06-05 | 한국생명공학연구원 | Composition comprising Euphorbia supina extract for preventing and treating inflammentary or allergic disease |
KR101359728B1 (en) * | 2013-03-25 | 2014-02-24 | 원광대학교산학협력단 | Composition containing fraction of euphorbia humifusa willd or euphorbia supina rafin for treating or preventing inflammatory disease |
Non-Patent Citations (1)
Title |
---|
Nugroho, Agung, et al. Archives of pharmacal research, 2014, 37(7), 890-898* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180106023A (en) | 2017-03-17 | 2018-10-01 | 한남대학교 산학협력단 | A pharmaceutical composition for preventing or treating obesity comprising seaweed extract and rosemary extract as an active ingredient |
KR102197241B1 (en) * | 2019-09-20 | 2020-12-31 | (주)엘파운더 | Composition for antioxidant and lipid differentiation inhibitory activity by ampk phosphorylation from fraction of ceramium kondoi |
Also Published As
Publication number | Publication date |
---|---|
WO2017030419A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
KR101785495B1 (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
KR101158856B1 (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient | |
KR20170005632A (en) | A composition comprising extract of Elaeagnus multiflora Thunb. for preventing or treating obesity or hyperlipidemia | |
KR20160123130A (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
KR101594979B1 (en) | Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. | |
KR101497109B1 (en) | Composition for preventing, improving, or treating a disease controlled by PPAR action | |
KR20120112137A (en) | Composition containing ethylacetate fraction of schisandra chinensis baillon or wuweizisu c isolated from the same for treating or preventing obesity | |
KR20130047458A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
KR101445966B1 (en) | A composition comprising Amomum cardamomum L. extracts having anti-obesity activity | |
KR20130081929A (en) | Composition comprising dieckol compound for treating insulin resistance or hyperinsulinemia | |
KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR101075554B1 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
KR20210000294A (en) | Pharmaceutical composition comprising the extract of Phlomis umbrosa Turczaninow as an effective ingredient for preventing or treating of obesity | |
KR101344564B1 (en) | Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia | |
KR102501548B1 (en) | A composition for improving, preventing and treating of fatty liver diseases comprising leek extract | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR102496751B1 (en) | Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it | |
KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
KR101578404B1 (en) | Composition for prevention or treatment of cancer containing extract or fraction of Euphorbia L. | |
KR102535521B1 (en) | Fruits of Acanthopanax Sessiliflorus extract including diabetes prevention functional ingredients and method for manufacturing it | |
KR102522975B1 (en) | An anti-obesity composition containing a fermented Moringa oleifera extract produced using a novel Monascus purpureus SL1 strain as an active ingredient | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20181206 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20191212 Year of fee payment: 5 |